drugset
drugset / Trial / NCT06041529

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

NCT06041529 ↗

Phase 4 Active not recruiting 198 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations

Timeline

Start
2023-10-18
Primary completion
2026-02-28
Completion
2026-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorthalidone Other / unclassified 12.5 mg Oral
Comparator Hydrochlorothiazide Unknown 25 mg Oral
Comparator Amlodipine Other / unclassified 5 mg Oral
Comparator Telmisartan Other / unclassified 40 mg Oral

Indications

essential hypertension